Related Experiment Videos
Fosphenytoin (Cerebyx)
1Department of Neurology, Boston University School of Medicine, Massachusetts, USA.
Clinical Neuropharmacology
|February 1, 1997
Summary
Fosphenytoin, a phenytoin prodrug, offers improved solubility and absorption compared to standard injectable phenytoin. It demonstrates reduced local toxicity and similar systemic effects, making it a viable alternative for epilepsy treatment.
Area of Science:
- Pharmacology
- Neurology
- Drug Development
Background:
- Standard injectable phenytoin has limitations including poor solubility and slower absorption.
- Fosphenytoin was developed as a water-soluble prodrug to overcome these limitations.
Purpose of the Study:
- To evaluate fosphenytoin as a safer and more effective alternative to injectable phenytoin.
- To assess fosphenytoin's efficacy and safety in various clinical settings.
Main Methods:
- Fosphenytoin's physicochemical properties (solubility, absorption) were compared to phenytoin.
- Clinical trials assessed fosphenytoin for intramuscular maintenance dosing, intramuscular loading dose, and intravenous treatment of status epilepticus.
- Local and systemic toxicity profiles were evaluated for both fosphenytoin and phenytoin.
Main Results:
- Fosphenytoin exhibits superior aqueous solubility and rapid intramuscular absorption.
- Successful clinical use was demonstrated for intramuscular maintenance and loading doses, and IV treatment of status epilepticus.
- Fosphenytoin showed reduced local toxicity (pain, burning, itching) compared to phenytoin.
- Systemic toxicity was similar, with less hypotension and more paresthesias observed with fosphenytoin.
Conclusions:
- Fosphenytoin is a well-tolerated and effective alternative to injectable phenytoin.
- Its improved pharmacokinetic profile and reduced local toxicity enhance patient care in epilepsy management.